Weight

Intermittent fasting has gained a following, in part because of tantalizing hints that it can boost cognition, fend off cancer and even slow aging

Ozempic and similar GLP-1 weight-loss medications are designed to be a lifelong treatment. But a new study finds the majority of people who use these drugs quit after just two years

Focusing on size in health care might be doing more harm than good.

Wegovy and similar weight-loss medications are becoming widely prescribed for teenagers with obesity, but little is known about their long-term effects

Dosing errors in the medication semaglutide, prescribed as Wegovy and Ozempic, can cause severe or prolonged gastrointestinal issues that require medical attention

A new generation of coffee concoctions on social media is putting the spotlight back on the drink’s possible weight-loss effects

Ozempic, Wegovy and other GLP-1 drugs are being investigated as treatments for many health conditions—from dementia to addiction to kidney problems

The neurons that produce a sick feeling and food aversion are distinct from those that induce a feeling of fullness

As the patents on various weight-loss drugs near expiration, companies in India and China are vying to make lower-cost versions that will widen access to such treatments

Semaglutide, the same compound in obesity drug Wegovy, slashes risk of kidney failure and death for people with type 2 diabetes

Many researchers think that Wegovy and Ozempic should be taken for life, but myriad factors can force people off the drugs

The FDA recently approved semaglutide (Wegovy) for preventing serious heart conditions in some people, but questions remain about how it works